

Emmanuel Androulakis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1841501/publications.pdf>

Version: 2024-02-01

70
papers

1,526
citations

430874

18
h-index

330143

37
g-index

71
all docs

71
docs citations

71
times ranked

3083
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes Mellitus-Associated Vascular Impairment. <i>Journal of the American College of Cardiology</i> , 2013, 62, 667-676.	2.8	230
2	The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 169-176.	3.9	132
3	White-coat hypertension and cardiovascular events. <i>Journal of Hypertension</i> , 2016, 34, 593-599.	0.5	131
4	Socioeconomic status and risk factors for cardiovascular disease: Impact of dietary mediators. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 32-42.	1.0	131
5	Pathophysiology of Atherosclerosis: The Role of Inflammation. <i>Current Pharmaceutical Design</i> , 2011, 17, 4089-4110.	1.9	96
6	Essential Hypertension. <i>Cardiology in Review</i> , 2009, 17, 216-221.	1.4	76
7	Fibrinogen and cardiovascular disease: Genetics and biomarkers. <i>Blood Reviews</i> , 2011, 25, 239-245.	5.7	64
8	Oxidative Stress and Early Atherosclerosis: Novel Antioxidant Treatment. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 75-88.	2.6	48
9	Inflammatory Markers in Essential Hypertension: Potential Clinical Implications. <i>Current Vascular Pharmacology</i> , 2010, 8, 509-516.	1.7	46
10	From Atherosclerosis to Acute Coronary Syndromes: The Role of Soluble CD40 Ligand. <i>Trends in Cardiovascular Medicine</i> , 2010, 20, 153-164.	4.9	36
11	Homoarginine in the shadow of asymmetric dimethylarginine: from nitric oxide to cardiovascular disease. <i>Amino Acids</i> , 2015, 47, 1741-1750.	2.7	33
12	Inflammation in Hypertension: Current Therapeutic Approaches. <i>Current Pharmaceutical Design</i> , 2011, 17, 4121-4131.	1.9	31
13	Improving the detection of preclinical organ damage in newly diagnosed hypertension: nocturnal hypertension versus non-dipping pattern. <i>Journal of Human Hypertension</i> , 2015, 29, 689-695.	2.2	23
14	Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies. <i>Heart Failure Reviews</i> , 2012, 17, 65-79.	3.9	22
15	Antioxidant Treatment and Endothelial Dysfunction: Is it Time for Flavonoids?. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2013, 8, 81-92.	1.5	22
16	Novel Therapeutic Approaches Targeting Matrix Metalloproteinases in Cardiovascular Disease. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 1214-1221.	2.1	21
17	Matrix Metalloproteinases in Acute Coronary Syndromes: Current Perspectives. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 1192-1205.	2.1	20
18	Clinical Utility of Biomarkers in Premature Atherosclerosis. <i>Current Medicinal Chemistry</i> , 2012, 19, 2521-2533.	2.4	19

#	ARTICLE	IF	CITATIONS
19	The Role of Cardiovascular Magnetic Resonance in Sports Cardiology; Current Utility and Future Perspectives. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 86.	0.9	18
20	Prognostic Role of miRNAs in Coronary Artery Disease. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 1540-1547.	2.1	18
21	Imaging Subclinical Atherosclerosis: Where Do We Stand?. <i>Current Cardiology Reviews</i> , 2016, 13, 47-55.	1.5	17
22	The Role of Matrix Metalloproteinases in Essential Hypertension. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 1149-1158.	2.1	16
23	Lp-PLA2 "A novel marker of atherosclerosis: To treat or not to treat?. <i>International Journal of Cardiology</i> , 2013, 165, 213-216.	1.7	15
24	Statins and Inflammation in Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2018, 23, 7027-7039.	1.9	14
25	Novel therapeutic strategies in the management of arterial hypertension. , 2012, 135, 168-175.		13
26	Subclinical Organ Damage in White Coat Hypertension: The Possible Role of Cystatin C. <i>Journal of Clinical Hypertension</i> , 2017, 19, 190-197.	2.0	13
27	Eosinophilic heart disease: diagnostic and prognostic assessment by cardiac magnetic resonance. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1273-1284.	1.2	13
28	Novel Biomarkers Assessing Endothelial Dysfunction: Role of microRNAs. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 1518-1526.	2.1	13
29	Novel therapeutic strategies targeting vascular endothelium in essential hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1395-1412.	4.1	12
30	Combined effects of fibrinogen genetic variability on atherosclerosis in patients with or without stable angina pectoris: Focus on the coagulation cascade and endothelial function. <i>International Journal of Cardiology</i> , 2013, 168, 4602-4607.	1.7	12
31	Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 288.	2.4	12
32	HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 907-921.	3.4	11
33	Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment. <i>Current Pharmaceutical Design</i> , 2019, 24, 4424-4435.	1.9	10
34	Lifestyle Factors and Endothelial Function. <i>Current Vascular Pharmacology</i> , 2012, 10, 94-106.	1.7	9
35	Meta-Analysis of Oral Anticoagulants with Dual versus Single Antiplatelet Therapy in Patients after Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 103-110.	2.2	9
36	Renin-Angiotensin System Inhibitors vs Other Antihypertensives in Hypertensive Blacks: A Meta-Analysis. <i>Journal of Clinical Hypertension</i> , 2017, 19, 344-350.	2.0	9

#	ARTICLE	IF	CITATIONS
37	High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes. <i>Current Cardiology Reviews</i> , 2017, 13, 168-182.	1.5	9
38	Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 1206-1213.	2.1	9
39	Genetic Predisposition to Left Ventricular Hypertrophy and the Potential Involvement of Cystatin-C in Untreated Hypertension. <i>American Journal of Hypertension</i> , 2013, 26, 683-690.	2.0	8
40	MicroRNAs in the Diagnosis and Treatment of Unstable Angina. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 1596-1604.	2.1	8
41	Statins and myocardial infarction: Type, dose, and administration time: Does it matter?. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 433-441.	4.9	7
42	The Impact of Antiplatelet Treatment on Endothelial Function. <i>Current Pharmaceutical Design</i> , 2016, 22, 4512-4518.	1.9	7
43	The Role of Cardiovascular Magnetic Resonance Imaging in the Assessment of Myocardial Fibrosis in Young and Veteran Athletes: Insights From a Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 784474.	2.4	7
44	Genetic polymorphism M235T of angiotensinogen: Effects on endothelial function and arterial stiffness in hypertensives. <i>International Journal of Cardiology</i> , 2012, 155, 501-503.	1.7	6
45	Effects of the C-344T aldosterone synthase gene variant on preclinical vascular alterations in essential hypertension. <i>International Journal of Cardiology</i> , 2013, 168, 1605-1606.	1.7	6
46	Coronary Artery Atherosclerosis in Hypertensive Patients: The Role of Fibrinogen Genetic Variability. <i>Revista Española De Cardiología (English Ed)</i> , 2017, 70, 34-41.	0.6	6
47	Inflammation and right ventricle: The hunting of the missing link. <i>International Journal of Cardiology</i> , 2013, 168, 3152-3154.	1.7	4
48	Heart Rate as a Therapeutic Target in Angina Pectoris. <i>Current Pharmaceutical Design</i> , 2013, 19, 1562-1568.	1.9	4
49	Hypertrophic cardiomyopathy or athlete's heart? A systematic review of novel cardiovascular magnetic resonance imaging parameters. <i>European Journal of Sport Science</i> , 2023, 23, 143-154.	2.7	4
50	Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. <i>Current Pharmaceutical Design</i> , 2020, 26, 5953-5968.	1.9	4
51	Insight to the Pathophysiology of Stable Angina Pectoris. <i>Current Pharmaceutical Design</i> , 2013, 19, 1593-1600.	1.9	3
52	The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque. <i>Current Pharmaceutical Design</i> , 2013, 19, 1651-1657.	1.9	3
53	Atherosclerosis coronaria en pacientes hipertensos: el papel de la variabilidad genética del fibrinógeno. <i>Revista Española De Cardiología</i> , 2017, 70, 34-41.	1.2	3
54	Spontaneous Coronary Artery Dissection: Insights From Cardiac Magnetic Resonance and Extracoronary Arterial Screening. <i>Circulation</i> , 2022, 145, 555-557.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Genetic Polymorphisms and the Vascular Endothelium. , 2015, , 129-142.		2
56	Chylopericardium associated with constrictive pericarditis assessed by multimodality imaging. Clinical Case Reports (discontinued), 2021, 9, e04354.	0.5	2
57	The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque. Current Pharmaceutical Design, 2013, 19, 1651-1657.	1.9	2
58	Reply. Journal of Hypertension, 2016, 34, 1658-1659.	0.5	1
59	Transcatheter mitral valve repair with MitraClip in patients with pulmonary hypertension: hemodynamic and prognostic perspectives. Reviews in Cardiovascular Medicine, 2021, 22, 33.	1.4	1
60	New Drugs and Interventional Strategies for the Management of Hypertension. Current Pharmaceutical Design, 2021, 27, 1396-1406.	1.9	1
61	Stable Angina Pectoris: Current Medical Treatment. Current Pharmaceutical Design, 2013, 19, 1569-1580.	1.9	1
62	Heart Rate as a Therapeutic Target in Angina Pectoris. Current Pharmaceutical Design, 2013, 19, 1562-1568.	1.9	0
63	Chronic thromboembolic pulmonary arterial hypertension: a review of the literature and novel therapeutic approaches. Expert Review of Respiratory Medicine, 2015, 9, 351-359.	2.5	0
64	Percutaneous Coronary Intervention Rates and Associated Independent Predictors for Progression of Nontarget Lesions in Patients With Diabetes Mellitus After Drug-Eluting Stent Implantation. Angiology, 2016, 67, 10-11.	1.8	0
65	Biological therapies targeting arrhythmias: are cells and genes the answer?. Expert Opinion on Biological Therapy, 2018, 18, 237-249.	3.1	0
66	Novel Anti-platelet Agents for the Treatment of Stable Angina Pectoris. Current Pharmaceutical Design, 2013, 19, 1581-1586.	1.9	0
67	Targeting Myocardial Metabolism for the Treatment of Stable Angina. Current Pharmaceutical Design, 2013, 19, 1587-1592.	1.9	0
68	Novel Biomarkers Used in the Assessment of Acute Coronary Syndrome. , 2013, , 345-362.		0
69	C-Reactive Protein in Cardiovascular Disease. , 2013, , 3-18.		0
70	Statins in Aortic Stenosis. Current Pharmaceutical Design, 2018, 23, 7121-7127.	1.9	0